Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Updates on German clinical trials in multiple myeloma

Marc Raab • 17 May 2019
COMy 2019
Multiple Myeloma Elotuzumab Isatuximab Lenalidomide
GMMG-MM5

Marc Raab, MD, PhD, of University Hospital Heidelberg, Heidelberg, Germany, gives an overview of recently concluded and ongoing German clinical trials looking at multiple myeloma (MM) treatment. For example, Prof. Raab discusses the results from the GMMG-MM5 trial (EudraCT no. 2010-019173-16), which compares a fixed two-year period of lenalidomide maintenance with stopping maintenance after complete remission. Prof. Raab also explains how two ongoing trials are likely to present interesting results on the role of monoclonal antibodies in first-line setting. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Marc Raab

2:03
Cobimetinib-based treatment for R/R multiple myeloma
Marc Raab • 8 Dec 2020
4:45
GMMG-Birma: BRAF and MEK inhibition in mutant BRAF V600E myeloma
Marc Raab • 8 Dec 2020
15:03
Translating myeloma genomics into treatment strategies
Gareth Morgan et al. • 14 Sep 2019
9:32
Multiple myeloma: genomic evolution
Jonathan Keats et al. • 18 Oct 2017

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals